Can the Plasma Concentration Ratio of Triglyceride/High-Density Lipoprotein Cholesterol Identify Individuals at High Risk of Cardiovascular Disease During 40-Year Follow-Up?

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 101150318 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-8518 (Electronic) Linking ISSN: 15404196 NLM ISO Abbreviation: Metab Syndr Relat Disord Subsets: MEDLINE
    • Publication Information:
      Original Publication: Larchmont, NY : Mary Ann Liebert, Inc., c2003-
    • Subject Terms:
      Insulin Resistance*; Cardiovascular Diseases/*blood ; Cholesterol, HDL/*blood ; Dyslipidemias/*blood ; Metabolic Syndrome/*blood ; Triglycerides/*blood; Biomarkers/blood ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/epidemiology ; Dyslipidemias/diagnosis ; Dyslipidemias/epidemiology ; Follow-Up Studies ; Humans ; Male ; Metabolic Syndrome/diagnosis ; Metabolic Syndrome/epidemiology ; Middle Aged ; Prognosis ; Risk Assessment ; Risk Factors ; Sweden/epidemiology ; Time Factors
    • Abstract:
      Background: The plasma concentration ratio of triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) is a simple way to estimate insulin resistance. We aimed to evaluate the TG/HDL-C ratio as a simple clinical way to identify apparently healthy individuals with insulin resistance and enhanced risk of future cardiovascular disease (CVD).
      Methods: One thousand seven hundred twenty men, aged 50 years, free from diabetes and CVD when evaluated at baseline in 1970-1974 were followed for 40 years regarding incident CVD (myocardial infarction and/or ischemic stroke, n = 576).
      Results: Participants with a high TG/HDL-C ratio (highest quartile >1.8) at baseline were more insulin resistant, with a significantly more adverse cardiometabolic risk profile (P < 0.001) at baseline, compared with those with a lower ratio. This group also showed an increased risk of CVD [hazard ratio, HR 1.47 (95% confidence interval 1.26-1.93) P < 0.001]. Fourteen percent of subjects with metabolic syndrome, in whom insulin resistance is increased, were also at enhanced CVD risk [HR 1.75 (1.42-2.16) P < 0.001].
      Conclusions: Twenty-five percent of apparently healthy 50-year-old men with the highest TG/HDL-C plasma concentration ratio had a significantly more adverse cardiometabolic profile at baseline, and developed more CVD over the next 40 years, compared with those not meeting this cut point. Determining the TG/HDL-C ratio in middle-aged men provided a simple and potentially clinically useful way to identify increased risk of developing CVD in persons free of diabetes or manifest CVD.
    • References:
      Int J Epidemiol. 2001 Oct;30 Suppl 1:S30-4. (PMID: 11759848)
      Metabolism. 2002 Feb;51(2):235-7. (PMID: 11833054)
      Scand J Soc Med. 1993 Mar;21(1):3-9. (PMID: 8469941)
      Diabetes Care. 2000 Feb;23(2):171-5. (PMID: 10868826)
      Curr Atheroscler Rep. 2003 Sep;5(5):364-71. (PMID: 12911846)
      Nat Genet. 2013 Nov;45(11):1345-52. (PMID: 24097064)
      Circulation. 2009 Oct 20;120(16):1640-5. (PMID: 19805654)
      Metabolism. 2013 Apr;62(4):548-53. (PMID: 23151437)
      Metabolism. 1999 Aug;48(8):989-94. (PMID: 10459563)
      J Intern Med. 2013 Jun;273(6):595-601. (PMID: 23331522)
      BMJ. 2006 Apr 15;332(7546):878-82. (PMID: 16510492)
      J Clin Endocrinol Metab. 2001 Aug;86(8):3574-8. (PMID: 11502781)
      J Lipid Res. 2013 Oct;54(10):2795-9. (PMID: 23863983)
      Clin Chem. 1972 Jun;18(6):499-502. (PMID: 4337382)
      Arterioscler Thromb Vasc Biol. 2011 May;31(5):954-5. (PMID: 21508339)
      J Investig Med. 2014 Feb;62(2):345-9. (PMID: 24402298)
      Am J Physiol. 1979 Sep;237(3):E214-23. (PMID: 382871)
      Diabetes Care. 2004 Aug;27(8):1998-2002. (PMID: 15277430)
      Biochem J. 1989 Jun 1;260(2):535-41. (PMID: 2669734)
      Am J Cardiol. 2012 Jun 15;109(12):1749-53. (PMID: 22449634)
      Lancet. 2012 Aug 11;380(9841):572-80. (PMID: 22607825)
      Nutr Metab Cardiovasc Dis. 2009 Jul;19(6):401-8. (PMID: 19091534)
      Ann Intern Med. 2003 Nov 18;139(10):802-9. (PMID: 14623617)
      J Intern Med. 1992 Jan;231(1):25-30. (PMID: 1732395)
      J Clin Endocrinol Metab. 1998 Aug;83(8):2773-6. (PMID: 9709945)
      Diabetes. 1981 May;30(5):387-92. (PMID: 7014307)
      Diabetologia. 1985 Jul;28(7):412-9. (PMID: 3899825)
      Lancet. 2011 Mar 26;377(9771):1085-95. (PMID: 21397319)
    • Grant Information:
      P30 DK116074 United States DK NIDDK NIH HHS
    • Contributed Indexing:
      Keywords: HDL-cholesterol; cardiovascular disease; metabolic syndrome; prospective; triglycerides
    • Accession Number:
      0 (Biomarkers)
      0 (Cholesterol, HDL)
      0 (Triglycerides)
    • Publication Date:
      Date Created: 20180906 Date Completed: 20190626 Latest Revision: 20191220
    • Publication Date:
      20240104
    • Accession Number:
      PMC6913120
    • Accession Number:
      10.1089/met.2018.0058
    • Accession Number:
      30183521